Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Effects of Diabetes and Hyperlipidemia in Physiological Conditions - A Review

Author(s): Sayan Hazra* and Gunosindhu Chakraborthy

Volume 21, Issue 3, 2025

Published on: 23 February, 2024

Article ID: e230224227362 Pages: 11

DOI: 10.2174/0115733998289406240214093815

Price: $65

Abstract

Background: Diabetes mellitus (DM) is an autoimmune manifestation defined by persistent hyperglycemia and alterations in protein, fatty substances, and carbohydrate metabolism as an effect of problems with the secretion of insulin action or both. Manifestations include thirst, blurred eyesight, weight loss, and ketoacidosis, which can majorly lead to coma. There are different types of diabetes according to class or by cellular level. They are interrelated with hyperlipidemia as they are involved in the metabolism and regulation of physiological factors. Most parameters are seen at cellular or humoral levels, yet the underlying concern remains the same.

Objective: To create a systematic correlation between the disease and locate the exact mechanism and receptors responsible for it. So, this article covers a proper way to resolve the conditions and their manifestation through literacy and diagrammatic.

Conclusion: Hence, this will be an insight for many scholars to understand the exact mechanism involved in the process.

Keywords: Diabetes, hyperglycemia, hyperlipidemia, autoimmune, ketoacidosis, insulin secretion.

[1]
WHO. Study group diabetes mellitus, Technical report series. World Health Organ Tech Rep Ser 1985; 727: 1-113.
[2]
Singh N, Kesherwani R, Tiwari AK, Patel DK. A review on diabetes mellitus. J Pharm Innov 2016; 5(7): 36-40.
[PMID: 27717130]
[3]
Kumar CR. Basic Pathology, Prism PVT. (5th ed.). Limited Bangalore 1992; pp. 569-87.
[4]
Ross and Wilson. Anatomy and pathophysiology in health and illness. (11th ed.). Churchill Livingstone Elsevier 2010; pp. 227-9.
[5]
Global burden of disease collaborative network. 2020. Available from: https://vizhub.healthdata.org/gbd-results/
[6]
Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20(7): 1183-97.
[http://dx.doi.org/10.2337/diacare.20.7.1183] [PMID: 9203460]
[7]
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(1): S81-90.
[PMID: 24357215] [http://dx.doi.org/10.2337/diacare.25.10.1862] [PMID: 12351492]
[8]
Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D, Zhang C. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. Arch Intern Med 2012; 172(20): 1566-72.
[http://dx.doi.org/10.1001/archinternmed.2012.3747] [PMID: 22987062]
[9]
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 2002; 25(10): 1862-8.
[10]
American diabetes association. Standards of medical care in diabetes--2014. Diabetes Care 2014; 37: S14-80.
[http://dx.doi.org/10.2337/dc14-S014] [PMID: 24357209]
[11]
Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361(14): 1339-48.
[http://dx.doi.org/10.1056/NEJMoa0902430] [PMID: 19797280]
[12]
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352(24): 2477-86.
[http://dx.doi.org/10.1056/NEJMoa042973] [PMID: 15951574]
[13]
Vandorsten JP, Dodson WC, Espeland MA, et al. NIH consensus development conference: Diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements 2013; 29(1): 1-31.
[PMID: 23748438]
[14]
Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43(8): 1066-85.
[http://dx.doi.org/10.2337/diab.43.8.1066] [PMID: 8039601]
[15]
Horvath K, Koch K, Jeitler K, et al. Effects of treatment in women with gestational diabetes mellitus: Systematic review and metaanalysis. BMJ 2010; 340(apr01 1): c1395.
[http://dx.doi.org/10.1136/bmj.c1395] [PMID: 20360215]
[16]
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104(6): 787-94.
[http://dx.doi.org/10.1172/JCI7231] [PMID: 10491414]
[17]
Surampudi PN, John-Kalarickal J, Fonseca VA. Emerging concepts in the pathophysiology of type 2 diabetes mellitus. Mt Sinai J Med 2009; 76(3): 216-26.
[http://dx.doi.org/10.1002/msj.20113] [PMID: 19421965]
[18]
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J 2012; 27(4): 269-73.
[http://dx.doi.org/10.5001/omj.2012.68] [PMID: 23071876]
[19]
Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
[http://dx.doi.org/10.1038/414782a] [PMID: 11742409]
[20]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
[http://dx.doi.org/10.2337/diacare.27.5.1047] [PMID: 15111519]
[21]
Deshmukh CD. Diabetes mellitus: A review. IJPAB 2015; 3(3): 224-30.
[22]
Bergman RN, Steil GM, Bradley DC, Watanabe RM. Modeling of insulin action in vivo. Annu Rev Physiol 1992; 54(1): 861-83.
[http://dx.doi.org/10.1146/annurev.ph.54.030192.004241] [PMID: 1562195]
[23]
Robertson RP. Antagonist: Diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995; 125(5): 560-4.
[PMID: 7738421]
[24]
Rang HP, Dale MM. Pharmacology, sixth edition, churchill livingstone. In: The Endocrine Pancreas and Control of Blood Glucose. Churchill Livingstone 2008; pp. 397-409.
[25]
Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6(10): 551-9.
[http://dx.doi.org/10.1038/nrneurol.2010.130] [PMID: 20842183]
[26]
Verma S, Gupta M, Popli H, Aggarwal G. Diabetes mellitus treatment using herbal drugs. Int J Phytomed 2018; 10(1): 01.
[http://dx.doi.org/10.5138/09750185.2181]
[27]
Tabatabaeimalazy O. Targeting metabolic disorders by natural products. J Diabetes Metab Disord 2015; 14-57.
[28]
Abutaleb MH. Diabetes Mellitus: An overview. Pharm Pharmacol Int J 2016; 4(5): 406-11.
[http://dx.doi.org/10.15406/ppij.2016.04.00087]
[29]
Joshi SK, Shrestha S. Diabetes mellitus: A review of its associations with different environmental factors. Kathmandu Univ Med J 2010; 8(29): 109-15. [KUMJ.
[PMID: 21209519]
[30]
Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. Indian J Ophthalmol 2009; 69(11): 2932-8.
[31]
Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl. 1): S64-71.
[PMID: 22187472]
[32]
American diabetes association. Standards of medical care in diabetes--2008. Diabetes Care 2008; 31: S12-54.
[http://dx.doi.org/10.2337/dc08-S012] [PMID: 18165335]
[33]
Schlichtmann J, Graber MA. Hematologic, electrolyte, and metabolic disorders. In: Graber MA, Toth PP, Herting RL, Eds. The Family Practice Handbook. (3rd ed.). St. Louis, Missouri: Mosby-Year Book Inc. 1997; pp. 192-251.
[34]
Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147(10): 1749-53.
[http://dx.doi.org/10.1001/archinte.1987.00370100063012] [PMID: 3310940]
[35]
Kartono A, Irawati FD, Setiawan AA, Syafutra H, Sumaryada T. The effects of physical exercise on the insulin-dependent diabetes mellitus subjects using the modified minimal model. Int J Pharm Pharm Sci 2017; 9(2): 179.
[http://dx.doi.org/10.22159/ijpps.2017v9i2.15621]
[36]
American diabetes association. Clinical practice recommendations 1995. Position statement: Diabetes mellitus and exercise. Diabetes Care 1995; 18: 28.
[http://dx.doi.org/10.2337/diacare.18.1.S28]
[37]
Thangasami SR, Chandani AL, Thangasami S. Emphasis of yoga in the management of diabetes. J Diabetes Metab 2015; 6(10): 2.
[http://dx.doi.org/10.4172/2155-6156.1000613]
[38]
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131(4): 281-303.
[http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00008] [PMID: 10454950]
[39]
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
[http://dx.doi.org/10.1056/NEJMoa072761] [PMID: 17517853]
[40]
Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26(6): 1902-12.
[http://dx.doi.org/10.2337/diacare.26.6.1902] [PMID: 12766131]
[41]
Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes 2002; 26(S3): S18-24.
[http://dx.doi.org/10.1038/sj.ijo.0802173] [PMID: 12174319]
[42]
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17): 1836-41.
[http://dx.doi.org/10.1001/archinte.166.17.1836] [PMID: 17000939]
[43]
Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: A population-based study in northern Sweden. Diabetes Care 2004; 27(4): 955-62.
[44]
Rathod S, Akshay J, Rode A, Shravan S. A review on diabetics. Int Multidiscip Res J 2023; 5(3): 1-13.
[http://dx.doi.org/10.2337/diacare.27.4.955] [PMID: 15047655]
[45]
Mumthaj P, Natarajan P, Janani AM. A global review article on hyperlipidemia. IJPSRR 2021; 68(1): 104-10.
[46]
Mishra PR, Panda PK, Apanna KC, Panigrahi S. Evaluation of acute hypolipidemic activity of different plant extracts in Triton WR-1339 induced pharmacologyonline. hyperlipidemia 2011; 3: 925-34.
[47]
DiPiro JT, Wells BG, Schwinghammer TL, DiPiro CV. Pharmacotherapy handbook. Appleton & Lange 2000.
[48]
Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am 1990; 19(2): 259-78.
[http://dx.doi.org/10.1016/S0889-8529(18)30324-4] [PMID: 2192873]
[49]
Goodman LS, Gilman A. The pharmacological basis of therapeutics. New York: Macmillan 1970.
[50]
Hassan B. Overview on hyperlipidemia. J Chromat Separation Techniq 2013; 4(2): 1.
[51]
Vijayaraj PS, Muthukumar K, Sabarirajan J, Naciappan V. IJBB 2011; 48: 54-8.
[52]
Kaliora AC, Dedoussis GVZ, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 2006; 187(1): 1-17.
[http://dx.doi.org/10.1016/j.atherosclerosis.2005.11.001] [PMID: 16313912]
[53]
Dhuley JN, Naik SR, Rele S, Banerji A. Hypolipidaemic and antioxidant activity of diallyl disulphide in rats. Pharm Pharmacol Commun 1999; 5(12): 689-96.
[http://dx.doi.org/10.1211/146080899128734406]
[54]
Shetgiri PP, D’Mello PM. Indian Drugs 2003; 40: 567-9.
[55]
Gopinathan N, Srinivasan KK, Mathew JE. Indian Drugs 2004; 41: 633-5.
[56]
Rajani GP, Ashok P. In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn. Indian J Pharmacol 2009; 41(5): 227-32.
[http://dx.doi.org/10.4103/0253-7613.58513] [PMID: 20177495]
[57]
Singh R, Nain S. A mini review on hyperlipidemia: Common clinical problem. J Interv Cardiol 2018; 10: 1-3.
[58]
Ranadive GN, Lala AK. Sterol-phospholipid interaction in model membranes: Role of C5-C6 double bond in cholesterol. Biochemistry 1987; 26(9): 2426-31.
[http://dx.doi.org/10.1021/bi00383a005] [PMID: 3607024]
[59]
Haines TH. Do sterols reduce proton and sodium leaks through lipid bilayers? Prog Lipid Res 2001; 40(4): 299-324.
[http://dx.doi.org/10.1016/S0163-7827(01)00009-1] [PMID: 11412894]
[60]
Esfahani M, Scerbo L, Devlin TM. A requirement for cholesterol and its structural features for a human macrophage‐like cell line. J Cell Biochem 1984; 25(2): 87-97.
[http://dx.doi.org/10.1002/jcb.240250204] [PMID: 6480716]
[61]
Vance D, Van den Bosch H. Cholesterol in the year 2000. Biochim Biophys Acta Mol Cell Biol Lipids 2000; 1529(1-3): 1-8.
[http://dx.doi.org/10.1016/S1388-1981(00)00133-5] [PMID: 11111073]
[62]
Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta Rev Biomembr 1985; 822(3-4): 267-87.
[http://dx.doi.org/10.1016/0304-4157(85)90011-5] [PMID: 3904832]
[63]
Miao L, Nielsen M, Thewalt J, et al. From lanosterol to cholesterol: Structural evolution and differential effects on lipid bilayers. Biophys J 2002; 82(3): 1429-44.
[http://dx.doi.org/10.1016/S0006-3495(02)75497-0] [PMID: 11867458]
[64]
Awad AB, Fink CS. Phytosterols as anticancer dietary components: Evidence and mechanism of action. J Nutr 2000; 130(9): 2127-30.
[http://dx.doi.org/10.1093/jn/130.9.2127] [PMID: 10958802]
[65]
Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290(5497): 1771-5.
[http://dx.doi.org/10.1126/science.290.5497.1771] [PMID: 11099417]
[66]
Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110(5): 597-603.
[http://dx.doi.org/10.1172/JCI0216390] [PMID: 12208858]
[67]
Prior IA, Hancock JF. Compartmentalization of Ras proteins. J Cell Sci 2001; 114(9): 1603-8.
[http://dx.doi.org/10.1242/jcs.114.9.1603] [PMID: 11309191]
[68]
Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab 2010; 7(1): 35.
[http://dx.doi.org/10.1186/1743-7075-7-35] [PMID: 20423497]
[69]
Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet 2010; 376(9738): 333-9.
[http://dx.doi.org/10.1016/S0140-6736(10)60713-1] [PMID: 20655105]
[70]
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: A report from the American Heart Association. Circulation 2016; 133(4): e38-e360.
[http://dx.doi.org/10.1161/CIR.0000000000000350] [PMID: 26673558]
[71]
Centers for disease control and prevention (CDC). Vital signs: Prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep 2011; 60(4): 109-14.
[PMID: 21293326]
[72]
Karr S. Epidemiology and management of hyperlipidemia. AJMC 2017; 23(9): S139-48.
[PMID: 28978219]
[73]
Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer’s disease. Neurology 2001; 57(6): 1089-93.
[http://dx.doi.org/10.1212/WNL.57.6.1089] [PMID: 11571339]
[74]
Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Ann Glob Health 2016; 82(2): 307-15.
[http://dx.doi.org/10.1016/j.aogh.2016.04.002] [PMID: 27372534]
[75]
Keane WF, St Peter JV, Kasiske BL. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int Suppl 1992; 38: S134-41.
[PMID: 1405364]
[76]
Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013; 40(1): 195-211.
[http://dx.doi.org/10.1016/j.pop.2012.11.003] [PMID: 23402469]
[77]
Pettersson C. Studies on the atherogenicity of Apo B containing lipoproteins in type 2 diabetes Institute of Medicine. Department of Molecular and Clinical Medicine 2009.
[78]
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63(25): 2889-934.
[http://dx.doi.org/10.1016/j.jacc.2013.11.002] [PMID: 24239923]
[79]
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311(8): 806-14.
[http://dx.doi.org/10.1001/jama.2014.732] [PMID: 24570244]
[80]
ACC/AHA. ACC/AHA ASCVD Risk Calculator website. 2016. Available from: www.cvriskcalculator.com(Accessed May 23, 2017).
[81]
Ito MK, Watts GF. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs 2015; 75(15): 1715-24.
[http://dx.doi.org/10.1007/s40265-015-0466-y] [PMID: 26370207]
[82]
Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype–phenotype relationship, and clinical outcome. Eur Heart J 2015; 36(9): 560-5.
[http://dx.doi.org/10.1093/eurheartj/ehu058] [PMID: 24585268]
[83]
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-90.
[http://dx.doi.org/10.1093/eurheartj/eht273] [PMID: 23956253]
[84]
Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing famil ial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67(22): 2578-89.
[http://dx.doi.org/10.1016/j.jacc.2016.03.520] [PMID: 27050191]
[85]
Naser IH, Alkareem ZA, Mosa AU. Hyperlipidemia: Pathophysiology, causes, complications and treatment, A Review. J Pharm Pharm Sci 2021; 118-32.
[86]
Hill MF, Bordoni B. Hyperlipidemia. In: StatPearls. Treasure Island, FL: StatPearls Publishing 2023.
[87]
Edeoga HO, Okwu DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. AJB 2005; 19(7): 685-8.
[88]
Cunningham AB. An investigation of the herbal medicine trade in Natal/KwaZulu. Institute of Natural Resources, University of Natal 1988.
[89]
Verma N. Introduction to hyperlipidemia and its treatment: A review. Int J Curr Pharm Res 2016; 9(1): 6-14.
[http://dx.doi.org/10.22159/ijcpr.2017v9i1.16616]
[90]
Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: Knowledge base, limitations, and future directions. Pediatrics 2007; 119(2): 370-80.
[http://dx.doi.org/10.1542/peds.2006-0787] [PMID: 17272627]
[91]
Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. McGraw-Hill 2011; pp. 877-908.
[92]
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72(1): 137-74.
[http://dx.doi.org/10.1146/annurev.biochem.72.121801.161712] [PMID: 12543708]
[93]
Safeer RS, Lacivita CL. Choosing drug therapy for patients with hyperlipidemia. Am Fam Physician 2000; 61(11): 3371-82.
[PMID: 10865931]
[94]
Harikumar K, Niveditha B, Reddy PK. Int J Phytopharm 2012; 3(3): 256-62.
[95]
Ahmed SM, Clasen MD, Donnelly MD. Managment of dyslipidemia in adults. Am Fam Physician 1998; 57: 1-16.
[96]
Diebold BA, Bhagavan NV, Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim Biophys Acta, Gen Subj 1994; 1200(2): 100-8.
[http://dx.doi.org/10.1016/0304-4165(94)90123-6] [PMID: 8031828]
[97]
Nirosha K, Divya M, Vamsi S, Mohemmed S. A review on hyperlipidemia. Int J Novel Trends Pharm Sci 2014; 4(5): 81-92.
[98]
Onwe PE, Folawiyo MA, Anyigor-Ogah CS, Umahi G, Okorocha AE, Afoke AO. J Med Dent Sci 2015; 14(10): 93-100.
[99]
Yuan G, Khalid Z. Hypertriglyceridemia: Its etiology, effects and treatment. Can Med Assoc 2007; 176(8): 1113-20.
[http://dx.doi.org/10.1503/cmaj.060963]
[100]
Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162(22): 2597-604.
[http://dx.doi.org/10.1001/archinte.162.22.2597] [PMID: 12456232]
[101]
Bhatt. Int J Physiol Pathophysiol Pharmacol 2010; 2(1): 57-63.
[PMID: 21383898]
[102]
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8(6): 1245-55.
[http://dx.doi.org/10.1016/S0735-1097(86)80293-5] [PMID: 3782631]
[103]
Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004; 58(7): 706-13.
[http://dx.doi.org/10.1111/j.1368-5031.2004.00233.x] [PMID: 15311728]
[104]
Bélichard P, Pruneau D, Zhiri A. Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster. Biochim Biophys Acta Lipids Lipid Metab 1993; 1169(1): 98-102.
[http://dx.doi.org/10.1016/0005-2760(93)90087-P] [PMID: 8334156]
[105]
McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47(8): 1584-7.
[http://dx.doi.org/10.1016/j.jacc.2005.11.072] [PMID: 16630994]
[106]
Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: Causes and consequences. J Clin Endocrinol Metab 2001; 86(3): 965-71.
[http://dx.doi.org/10.1210/jcem.86.3.7304] [PMID: 11238470]
[107]
Ginsberg HN. Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996; 45: S27-30.
[http://dx.doi.org/10.2337/diab.45.3.S27] [PMID: 8674885]
[108]
Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5(5): 339-49.
[http://dx.doi.org/10.1097/00041433-199410000-00005] [PMID: 7858908]
[109]
Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101(9): 975-80.
[http://dx.doi.org/10.1161/01.CIR.101.9.975] [PMID: 10704163]
[110]
Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 1991; 266(8): 5080-6.
[http://dx.doi.org/10.1016/S0021-9258(19)67758-6] [PMID: 1848237]
[111]
Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275(12): 8416-25.
[http://dx.doi.org/10.1074/jbc.275.12.8416] [PMID: 10722675]
[112]
De Man FHAF, Castro Cabezas M, Van Barlingen HHJJ, Erkelens DW, De Bruin TWA. Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996; 26(2): 89-108.
[http://dx.doi.org/10.1046/j.1365-2362.1996.114256.x] [PMID: 8904518]
[113]
Lewis GF, O’Meara NM, Soltys PA, et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991; 72(4): 934-44.
[http://dx.doi.org/10.1210/jcem-72-4-934] [PMID: 2005221]
[114]
Lewis GF, O’Meara NM, Cabana VG, et al. Postprandial triglyceride response in Type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement. Diabetologia 1991; 34(4): 253-9.
[http://dx.doi.org/10.1007/BF00405084] [PMID: 2065859]
[115]
Ebara T, Conde K, Kako Y, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105(12): 1807-18.
[http://dx.doi.org/10.1172/JCI8283] [PMID: 10862796]
[116]
Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274(27): 19055-62.
[http://dx.doi.org/10.1074/jbc.274.27.19055] [PMID: 10383407]
[117]
Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991; 32(4): 559-68.
[http://dx.doi.org/10.1016/S0022-2275(20)42043-7] [PMID: 1856605]
[118]
Véniant MM, Pierotti V, Newland D, et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997; 100(1): 180-8.
[http://dx.doi.org/10.1172/JCI119511] [PMID: 9202070]
[119]
Goldberg IJ, Le NA, Ginsberg HN, Krauss RM, Lindgren FT. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. J Clin Invest 1988; 81(2): 561-8.
[http://dx.doi.org/10.1172/JCI113354] [PMID: 3276735]

Rights & Permissions Print Cite
Article Metrics
11
Wayfinder Image
World Diabetes Day
© 2024 Bentham Science Publishers | Privacy Policy